SCHEDULE 13G/A: Goldman Sachs Discloses Continued 5.2% Passive Stake in Syndax Pharmaceuticals
Beneficial Ownership Report
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amendment to their Schedule 13G, reaffirming a beneficial ownership of 5.2% in Syndax Pharmaceuticals, Inc.'s common stock as of March 31, 2025.
Summary
- The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly reported beneficial ownership of 4,510,669.26 shares of Syndax Pharmaceuticals, Inc. common stock.
- This aggregate amount represents 5.2% of Syndax Pharmaceuticals, Inc.'s outstanding common stock.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported passive investment.
- The reporting persons, The Goldman Sachs Group, Inc. (Delaware) and Goldman Sachs & Co. LLC (New York), hold these securities in the ordinary course of business.
- The investment is stated not to be for the purpose of or with the effect of changing or influencing the control of Syndax Pharmaceuticals, Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing beneficial ownership and does not contain information that would significantly alter sentiment, as it's a standard disclosure of an institutional stake.
Positives
- The disclosure of a significant institutional holding by a major financial entity like Goldman Sachs can be perceived as a vote of confidence in Syndax Pharmaceuticals, Inc.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Syndax Pharmaceuticals, Inc.'s future performance or strategic direction. It is solely a beneficial ownership disclosure.
Industry Context
This filing represents a routine disclosure of a passive institutional investment by a major financial services firm (Goldman Sachs) in a biotechnology/pharmaceutical company (Syndax Pharmaceuticals). Such filings are common and reflect standard portfolio management activities rather than specific strategic moves related to the issuer's industry trends.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder, which may influence investor perception and confidence.
Key Dates
| Date | Description |
|---|---|
| 2024-07-29 | Date of signing for The Goldman Sachs Group, Inc. Power of Attorney, effective until July 29, 2025. |
| 2024-10-01 | Date of signing for Goldman Sachs & Co. LLC Power of Attorney, effective until October 1, 2025. |
| 2025-03-31 | Date of event which requires the filing of this statement. |
| 2025-04-02 | Date of signature for the Schedule 13G filing by both The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC, and the Joint Filing Agreement. |
Keywords
Syndax Pharmaceuticals, Goldman Sachs, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.